Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 05, 2002 FBO #0277
SOLICITATION NOTICE

A -- Study of Medication Use and Risk of Esophageal Adenocarcinoma and Barrett''s Esophagus

Notice Date

9/3/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20133-NG
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational Epidemiology Branch (OEB) plans to procure services from Group Health Cooperative of Puget Sound, 1730 Minor Avenue, Suite 1600, Seattle, Washington 98101 for a Pilot Study of Medication Use and Risk of Esophageal Adenocarcinoma and Barrett=s Esophagus. The supplies and services herein are non-commercial as defined in FAR Part 13, are being procured in accordance with simplified procedures. The North American Industry Classification System code is 541710 and the business size standard is 500 employees. The Occupational Epidemiology Branch plans to examine the association between medications that relax the lower esophageal sphincter (LES) and the risk of esophageal adenocarcinoma and Barrett=s esophagus. The analyses must address the following public health questions: i) the risk of esophageal adenocarcinoma and Barrett=s esophagus related to the use of specific medications, ii) the risk associated with the use of combinations of such medications, iii) the dose-response relations in terms of both duration of use and prescribed dose, and iv) the associations between esophageal adenocarcinoma and certain medical conditions potentially on the causal pathway, such as Barrett=s esophagus and gastroesophageal reflux disease (GERD). Previous studies that examined the relationship between medication use and esophageal adenocarcinoma relied on self-reported medication use information, which is subject to both differential and nondifferential misclassification. To overcome the limitations associated with self-reported data, new analyses must use accurate, objective, and detailed medication use data (including prescribed dose, frequency of prescription refills, and duration of use) in conjunction with detailed information on the cancer and other medical conditions of interest. Minimum Requirements: 1) Contractor must have access to large study population of at least 500,000 men and women with prepaid health care, with detailed prospective data on prescription medication use, selected medical conditions, and cancer outcomes. This data must be available for epidemiologic analysis; 2) have sufficient power to assess the relationship between individual medication use and risk of esophageal Adenocarcinoma; 3) the study needs to have detailed long-term computerized data on medication use, and that data must be linked to patients diagnosed with esophageal Adenocarcinoma and other medical conditions being examined and; 4) Contractor shall be familiar with the epidemiologic analyses required, and for interpreting the results. Group Health Cooperative is the only source known to NCI that can meet the above specifications. NCI is familiar with the sources of such cohorts and data within the United States and believes that Group Health Cooperative is uniquely capable of efficiently providing the required number of esophageal adenocarcinoma and Barrett=s esophagus cases as well as the necessary exposure and disease information. This collaboration will further promote the goals of the NCI-CRN Cooperative Agreement, which is intended to foster such collaborations. Results of this pilot study are necessary to determine the feasibility of a larger, more extensive study additionally incorporating abstraction of medical records at this or other CRN sites. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on September 10, 2002. If you have and questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NCI/NIH, 9000 Rockville Pike, Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00156352-W 20020905/020903213132 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |